Developing science,delivering therapies
We are pioneers in harnessing bacteria as a revolutionary new class of medicines – called live biotherapeutics.
From asthma to cancer, we conduct world-leading research to identify live biotherapeutics with drug-like functionality to treat a range of diseases.
We are uniquely positioned to rapidly translate our research into regulated, safe and efficacious therapies for patients.
For the period ended 31 December 2016
First clinical trial of its proprietary diagnostic platform, MicroDx.
Update on phase 1 clinical trial in respect of Blautix